SyncThink Revenue and Competitors

COMPANY OVERVIEW SyncThink (www.syncthink.com) is a leading neuro-technology company with foundational IP in eye-tracking metrics and devices. The Company was founded in 2009 by Dr. Jam Ghajar, Neurosurgeon, founder of the Brain Trauma Foundation and director of the Stanford Concussion and Brain Performance center. SyncThink is headquartered in Palo Alto, CA with an affiliate office in New York City. Highlights of the Company include: - World Class Partnerships: Partnered/affiliated with leading research institutions and practitioners including the Brain Trauma Foundation (“BTF”), and Stanford University. - Millions in Research and Development: SyncThink and BTF have successfully secured over $28 million in technology development and research contracts from US Department of Defense since 2008. - Numerous Applications with FDA Approval: Initial focus on neuro-assessment in military and athletics. Broader set of potential applications include attention development in children, enhancing brain performance, fatigue evaluation, pharmaceutical, among others. The EYE-SYNC device has been FDA approved. - Proprietary Software Technology: Eleven issued patents (with additional six patents pending) covering hardware, analytics, market applications and scientific platform. TECHNOLOGY The EYE-SYNC device is a fully-integrated, head-mounted eye-tracking device for rapid, reliable screening of attention focus related impairment. The solution is non-invasive, low-risk, and highly reliable. As a subject tracks a predictable moving target that follows a circular trajectory on a screen within the head mounted device, eye movements are recorded by high speed cameras. Embedded systems software characterizes eye-target synchronization and the results are displayed and stored on a handheld peripheral for instant impairment screening. The benefits of the EYE-SYNC technology are speed (takes less than 60 seconds), accuracy, portability, and proven metrics.